{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T19:50:15Z","timestamp":1777751415712,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173674"],"award-info":[{"award-number":["82173674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204195"],"award-info":[{"award-number":["82204195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872734"],"award-info":[{"award-number":["81872734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220730"],"award-info":[{"award-number":["BK20220730"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bioorg.2024.107405","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T11:12:35Z","timestamp":1714129955000},"page":"107405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel CCR3-targeted cyclic peptides as potential therapeutic agents for age-related macular degeneration via inhibiting angiogenesis and reducing retinal photoreceptor damage"],"prefix":"10.1016","volume":"147","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu'ai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiale","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.4266","article-title":"Mechanisms of age-related macular degeneration and therapeutic opportunities","volume":"232","author":"van Lookeren Campagne","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.bioorg.2024.107405_b0010","unstructured":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet. Global health 2021, 9 (2), e144-e160."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0015","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107405_b0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/14712598.2012.660523","article-title":"Ranibizumab for age-related macular degeneration","volume":"12","author":"Dhoot","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bioorg.2024.107405_b0025","first-page":"2355","article-title":"Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration","volume":"9","author":"Balaratnasingam","year":"2015","journal-title":"Clinical Ophthalmology (auckland, n.z.)"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107405_b0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.107405_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107405_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond.)"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020516","article-title":"Chemokine Receptors-Structure-Based Virtual Screening Assisted by Machine Learning","volume":"15","author":"Dragan","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2024.107405_b0055","doi-asserted-by":"crossref","unstructured":"Salcedo, R.; Young, H. A.; Ponce, M. L.; Ward, J. M.; Kleinman, H. K.; Murphy, W. J.; Oppenheim, J. J., Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. Journal of immunology (Baltimore, Md. : 1950) 2001, 166 (12), 7571-8.","DOI":"10.4049\/jimmunol.166.12.7571"},{"issue":"7252","key":"10.1016\/j.bioorg.2024.107405_b0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","article-title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy","volume":"460","author":"Takeda","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107405_b0065","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.1167\/iovs.11-8230","article-title":"Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling","volume":"52","author":"Wang","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"32","key":"10.1016\/j.bioorg.2024.107405_b0070","doi-asserted-by":"crossref","first-page":"19972","DOI":"10.1074\/jbc.273.32.19972","article-title":"The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation","volume":"273","author":"Pease","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0075","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1167\/iovs.11-9095","article-title":"Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist","volume":"54","author":"Mizutani","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107405_b0080","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.ajpath.2015.04.029","article-title":"Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability","volume":"185","author":"Nagai","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107405_b0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia-Pacific J. Ophthalmol. (Philadelphia Pa.)"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107405_b0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nri2972","article-title":"Overcoming hurdles in developing successful drugs targeting chemokine receptors","volume":"11","author":"Schall","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2024.107405_b0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejphar.2014.06.060","article-title":"Chemokine receptors as therapeutic targets: Why aren't there more drugs?","volume":"746","author":"Solari","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107405_b0100","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2174\/0929866525666181114155542","article-title":"Building on success: a bright future for peptide therapeutics","volume":"25","author":"Angell","year":"2018","journal-title":"Protein Pept. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107405_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107405_b0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pro.3744","article-title":"Structural basis of chemokine and receptor interactions: Key regulators of leukocyte recruitment in inflammatory responses","volume":"29","author":"Bhusal","year":"2020","journal-title":"Protein Science"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107405_b0115","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1002\/1521-4141(200112)31:12<3535::AID-IMMU3535>3.0.CO;2-3","article-title":"Functional inhibition of CCR3-dependent responses by peptides derived from phage libraries","volume":"31","author":"Houimel","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107405_b0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107405_b0125","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0185-16.2016","article-title":"High-content genome-wide RNAi screen reveals CCR3 as a key mediator of neuronal cell death","volume":"3","author":"Zhang","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.bioorg.2024.107405_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2019.05.022","article-title":"The small molecular CCR3 antagonist YM344031 attenuates neurodegenerative pathologies and improves learning and memory performance in a mouse model of Alzheimer's disease","volume":"1719","author":"Sui","year":"2019","journal-title":"Brain Res."},{"issue":"35","key":"10.1016\/j.bioorg.2024.107405_b0135","doi-asserted-by":"crossref","first-page":"27250","DOI":"10.1016\/S0021-9258(19)61504-8","article-title":"Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3","volume":"275","author":"Ye","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2024.107405_b0140","doi-asserted-by":"crossref","first-page":"15123","DOI":"10.1021\/acs.jmedchem.2c00968","article-title":"In silico exploration and biological evaluation of bispecific peptides derived from Anti-HER2 antibodies and peptide-camptothecin conjugates for HER2-positive breast cancer","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107405_b0145","first-page":"e53502","article-title":"A Mouse Model for Laser-induced Choroidal Neovascularization","volume":"106","author":"Shah","year":"2015","journal-title":"J. Visualized Experiments: Jove"},{"key":"10.1016\/j.bioorg.2024.107405_b0150","article-title":"Dissection of a mouse eye for a whole mount of the retinal pigment epithelium","volume":"48","author":"Claybon","year":"2011","journal-title":"J. Visualized Experiments: Jove"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:57:17Z","timestamp":1777463837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0045206824003109"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107405","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel CCR3-targeted cyclic peptides as potential therapeutic agents for age-related macular degeneration via inhibiting angiogenesis and reducing retinal photoreceptor damage","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107405"}}